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Background: There is growing interest in defining the somatic 
mutations associated with small-cell lung cancer (SCLC). 
Unfortunately, a serious blockade to genomic analyses of this dis-
ease is a limited access to tumors because surgery is rarely per-
formed. We used our clinical/pathologic database of SCLC patients 
to determine the availability of biopsy specimens that could be 
used for genomic studies and to identify tumors for initial onco-
gene analysis.
Methods: DNA was extracted from six tumors, three primary and 
three metastatic, and analyzed by SEQUENOM platform technology.
Results: Primary-resected tumor tissue represents less than 3% of all 
diagnostic specimens in this disease, highlighting the limited access 
to tissue sufficient for comprehensive genomic analyses. We iden-
tified an activating M918T RET somatic mutation in a metastatic 
SCLC tumor specimen. Bioinformatic search identified RET muta-
tions in other SCLC studies. Stable overexpression of both mutant 
M918T and wild-type RET in two SCLC cell lines, H1048 and 
SW1271, activated ERK signaling, MYC expression, and increased 
cell proliferation, particularly by mutant RET. Stable cells became 
sensitized to the RET tyrosine kinase inhibitors, vandetanib and 
ponatinib. Further analysis of RET mRNA expression in SCLC 
revealed wide variability in both cells and tumors, and SCLC cells 
demonstrated significantly higher RET expression compared with 
adenocarcinoma lung cells.
Conclusions: Our data suggest that a subpopulation of SCLC 
patients may derive benefit from tyrosine kinase inhibitors target-
ing RET. Coupled with the presence of RET fusion proteins in non-
small-cell lung cancer, our data indicate an emerging role for RET 
in SCLC.
Key Words: RET, Small-cell lung cancer, Oncogene, SNP, Tyrosine 
kinase inhibitors.
(J Thorac Oncol. 2014;9: 1316–1323)
Small-cell lung cancer (SCLC) is a highly malignant pulmo-nary neuroendocrine tumor representing 15% of all lung 
carcinomas and is strongly associated with cigarette smoking.1,2 
Patients with SCLC are classified as having either limited dis-
ease or extensive disease depending on whether the cancer has 
metastasized beyond one hemithorax. Given that more than 
70% of all SCLC patients present with widely extensive dis-
ease, chemotherapy is the only treatment option. Unfortunately, 
all patients will relapse and the effectiveness of second-line 
therapies is limited. No significant improvement in SCLC treat-
ment has emerged over the past 30 years.3 Molecular targeting 
approaches that have been successful against non–small-cell 
lung cancer (NSCLC), such as erlotinib and crizotinib, have 
been unsuccessful against SCLC.4,5 These failures suggest that 
fundamental biological differences exist between these two sub-
types of lung cancer. Although SCLC is not included in The 
Cancer Genome Atlas, there is a growing interest in defining 
the somatic mutations associated with SCLC, as evidenced 
by two recent publications featuring comprehensive genomic 
analyses of SCLC tumors.6,7 A major limitation of these studies, 
however, is that mostly primary tumors were analyzed, likely 
obtained from a rare subgroup of patients with SCLC that have 
undergone surgical resection for very early stage disease and 
most likely represents a distinct biological behavior that may 
not be representative of the majority of patients.
We maintain a clinical/pathological database of all 
SCLC patients presenting at our medical center. We used this 
database to quantitate the distribution of diagnostic speci-
mens available for genomic analysis. Furthermore, we ini-
tially selected six tumors for oncogene analysis and identified 
an activating somatic RET M918T mutation in a metastatic 
tumor. The downstream effects of stable overexpression of this 
RET mutant and wild-type RET in cultured SCLC cells were 
examined. Our results demonstrate that RET may represent a 
new target for tyrosine kinase inhibition in a subset of SCLC.
MATERIALS AND METHODS
Tumor Specimens
Our study was approved by our local Institutional 
Review Board. All SCLC patients presenting between 2000 
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and 2012 for whom pathological diagnosis was obtained at our 
institution were eligible for this database. All obtained diag-
nostic specimens were recorded. Those which were obtained 
in the initial diagnostic process were considered as the first 
or primary diagnostic samples. A total of 422 patients are 
included in our database, of which 412 had diagnostic pathol-
ogy samples. The mean age of the cohort was 66.2 ± 10.6 (SD) 
years, and the median overall survival of patients was 10.9 
months. Further descriptive statistics for the SCLC cohort are 
given in Supplemental Table 1 (Supplemental Digital Content 
1, http://links.lww.com/JTO/A675).
Molecular Biology
DNA from tumors of six different patients was prepared 
using two to three slides of formalin-fixed paraffin-embedded 
tissue, using a QIAmp DNA formalin-fixed paraffin-embed-
ded kit (Qiagen, Valencia, CA). All specimens were at least 
75% tumor. The primary tumors (no. 12, 16, 18) were periph-
eral in location and surgically resected. The SCLC metastatic 
tumors were from the brain (no. 22), pancreas (no. 182), and 
adrenal gland (no. 162). Additional descriptive features for the 
six patients are given in Supplemental Table 1 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A675). The tumor 
DNA was analyzed by SEQUENOM (San Diego, CA) using 
their platform technology called OncoCarta, which consists 
of multiplexed polymerase chain reaction (PCR) assays that 
are run on each sample and analyzed by subsequent matrix-
assisted laser desorption ionization–time-of-flight (MALDI-
TOF) mass spectroscopy. The OncoCarta panel of reagents 
assays for 238 somatic mutations across 19 common onco-
genes (ABL-1, AKT-1 & 2, BRAF, CDK-4, EGFR, ERBB2, 
FGFR-1 & 3, FLT-3, JAK-2, KIT, MET, PDGFRα, PIK3CA, 
H-, K-, and N-RAS, and RET) and detects single base muta-
tions, insertions, and deletions. The output of this assay reports 
the relative frequency of the mutated and expected wild-type 
sequences (see Supplemental Figure 1, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A675).
RET mutations were verified by Sanger sequencing. 
The forward primer was 5′-actgaaagctcagggataggg-3′ and 
the reverse primer was 5′-catttgcctcacgaacacatc-3′ for ampli-
fication of RET exon 16 containing the mutation. A 357-bp 
product was generated containing the 71-bp exon, using an 
annealing temperature of 60°C and 30 cycles of PCR. We 
also performed targeted exon sequencing of exons 11 to 19 
of RET in DNA isolated from 46 SCLC cell lines, 20 primary 
and 8 metastatic SCLC tumors. The exon sequencing results 
were not validated. The potential structural and functional 
effects of amino acid mutations in RET were predicted using 
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT 
Human Protein DB (http://sift.jcvi.org/) using the longer RET-
51 isoform.
RET Receptor Stable Cell Culture and Treatment
Human small-cell lung carcinoma cell lines NCI 
H1048 and SW1271 were purchased from American Type 
Culture Collection (Manassas, VA). Cells were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM)/Ham’s 
F-12, 1:1 supplemented with 10% (v/v) fetal bovine serum 
(Hyclone, South Logan, UT) in a 5% carbon dioxide humidi-
fied incubator at 37°C. Cells were seeded for transfection at 
1 × 105 cells per well in 6-well plates. TransIT-2020 (Mirus, 
Madison, WI) was used as the transfection reagent with 1 μg 
of either pcDNA-RET wild type or pcDNA-RET M918T in 
DMEM/F12 media without serum. Both constructs contained 
the shorter, RET-9 isoform. After 5 hours of incubation, media 
was replaced with DMEM/F12 media containing fetal bovine 
serum (10%). Stable transfectants were isolated by selection 
for 2 weeks in 1 mg/ml G418 (Sigma, St. Louis, MO). Clones 
were collectively trypsinized to form a pool of stable cells.
In ERK phosphorylation experiments, 2 × 105 cells were 
initially seeded into 6-well plates. After an overnight incuba-
tion in complete medium, cells were switched to serum-free 
medium for 24 hours. Cells were then stimulated with 5 or 
50 ng/ml GDNF (Gibco/Life Technologies, Grand Island, NY) 
for 10 minutes, then protein lysates were prepared.
Quantitative Real-Time PCR
Cells were harvested under exponential growth condi-
tions. RNA was extracted using the RNeasy Mini Kit (Qiagen), 
digested with DNase I (Promega, Madison, WI), and reverse 
transcription was performed using a Superscript III First 
Strand synthesis kit for real-time PCR (Invitrogen, Carlsbad, 
CA). Real-time PCR was performed using TaqMan Fast 
Universal Master Mix and the TaqMan probe for human RET 
(Hs01120030) on an Applied Biosystems 7500 Fast Sequence 
Detection System according to the manufacturer’s instruc-
tions (Applied Biosystems, Foster City, CA). Samples were 
run in triplicate and standardized against endogenous β-actin 
(Human ACTB Endogenous Control, Applied Biosystems). 
The resulting relative RET mRNA amounts in each sample 
(∆CT = RET CT − ACTB CT) were normalized to control 
values (∆∆CT) to yield fold changes.
Immunoblotting and Antibodies
Cells were washed with cold phosphate-buffered saline 
(PBS), resuspended in radioimmunoprecipitation assay 
(RIPA) lysis buffer, and centrifuged at 12,000g for 4 minutes. 
The supernatant was collected and stored at −80°C. Protein 
concentrations were estimated using Bradford reagent (Bio-
Rad, Hercules, CA). Equal amounts of protein were loaded 
for immunoblotting. After SDS-PAGE, resolved proteins 
were electroblotted onto immobilon polyvinylidene difluoride 
(PVDF) membrane. The membrane was blocked overnight 
in PBS containing 0.1% Tween-20 (PBST) and 5% bovine 
serum albumin. The membrane was then probed with pri-
mary antibody in PBST/5% milk for 2 hours at room tem-
perature or overnight at 4°C, followed by three 10-minute 
PBST washes at room temperature. Secondary antibody in 
PBST/5% milk was incubated for 1 hour, followed by three 
10-minute PBST washes before chemiluminescence detec-
tion using ECL Plus substrate (Amersham, GE Healthcare, 
Piscataway, NJ). Antibodies used for western blots were total 
Ret (sc-13104), total Erk (sc-94), and p-Erk (sc-7383) from 
Santa Cruz Biotechnology (Santa Cruz, CA), c-Myc from 
Abcam (Cambridge, MA), and β-actin (A5441) from Sigma.
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Cell Proliferation Assays
Cell proliferation was assayed as percent confluence 
using an IncuCyte ZOOM (ESSEN Bioscience, Ann Arbor, 
MI) in 24-well dishes. Briefly, 5 × 104 parental or RET-receptor 
stable cells were seeded per well. After overnight incubation 
in complete medium, cells were switched to serum-free con-
ditions for the rest of the experiment. The percent confluence 
was measured every 2 hours for 8 days. Results show the aver-
age of triplicate wells.
Cell proliferation was also determined by the MTT assay 
using a CellTiter 96 AQueous One Solution Cell Proliferation 
Assay Kit (Promega). Approximately 2 × 104 cells were added 
to each well of a 96-well plate in 100 μl of complete medium. 
After overnight incubation, cells were switched to serum-free 
conditions for the rest of the experiment. Four days later, 20 
μl of CellTiter 96 AQueous One Solution was added to each 
well and the plates were further incubated for 2 hours at 37°C. 
Absorbance was measured at 490 nm with a 96-well plate 
reader. In some experiments, cells were continuously treated 
for the indicated times with various doses of either vandetanib 
or ponatinib (Selleckchem, Houston, TX). Drug was admin-
istered 1 day after the initial seeding and growth inhibition 
measured in complete medium. All experimental conditions 
were assayed in triplicate.
Statistics
RET mRNA expression in SCLC cells was compared 
with that of NSCLC cells by multiple comparisons tests after 
one-way analysis of variance, using GraphPad PRISM soft-
ware (La Jolla, CA).
Immunohistochemistry
The MaxArray Human Lung Cancer Tissue Microarray 
was obtained from InVitrogen (Camarillo, CA). Antibodies 
used in immunohistochemistry were total RET (HPA008356) 
from Sigma and p-MAPK (Erk 1/2) (no. 4376) from Cell 
Signaling Technology. Immunohistochemistry was scored 
by a thoracic pathologist on a scale of 0 (<5%), 1+ (5–25%), 
2+ (25–50%), or 3+ (>50%), depending on the percentage of 
tumor cells staining positive for RET.
RESULTS
Distribution of SCLC Diagnostic Samples
The distribution of primary diagnostic samples, seg-
regated by disease stage, in our SCLC cohort of patients is 
shown in Figure 1. Biopsy was the main procedure for initial 
diagnosis of both extensive (77%) and limited (71%) disease 
patients. Of particular note, however, surgical samples were 
the first diagnostic specimen in only 11 cases, all from limited 
disease patients, representing only 2.7% of all specimens.
RET Mutations in SCLC Tumors
We initially used our database to find six SCLC speci-
mens, three primary and three metastatic, having sufficient 
tissue for genomic analysis. We detected only two high-
confidence mutations by SEQUENOM analysis, a RET 
(rearranged during transfection, GDNF receptor) M918T 
mutation in a brain metastasis (no. 22) and a MET (met pro-
tooncogene, hepatocyte growth factor receptor) R970C muta-
tion in a primary tumor (no. 18) (see Supplemental Figure 1, 
Supplemental Digital Content 2, http://links.lww.com/JTO/
A675). Both were present at high allelic frequency (63% and 
52%, respectively), indicating their potential as “driver” muta-
tions. We selected the RET M918T mutation for further inves-
tigation because of its strong association with the MEN2B 
syndrome of medullary thyroid cancer (MTC),8,9 a disease that 
also has neuroendocrine features. The activating MET R970C 
mutation (also termed R988C) was previously reported in 
two SCLC cell lines but could not be found in a cohort of 
33 SCLC tumors.10
We validated the RET M918T mutation in the tumor 
by Sanger sequencing, and its absence in a matched skin 
biopsy, establishing its somatic nature (see Supplemental 
Figure 2, Supplemental Digital Content 2, http://links.lww.
com/JTO/A675). RET expression in the tumor was confirmed 
by immunohistochemistry (Fig. 2). We next performed our 
own targeted sequencing of exons 11 to 19 of RET, contain-
ing the tyrosine kinase domain, in an additional cohort of 20 
primary and 8 metastatic SCLC tumors and 46 SCLC cell 
lines and found no RET mutations in the tumors but five cell 
FIGURE 1.  Distribution of primary biopsy samples 
in small-cell lung cancer diagnosis. The number 
in parentheses indicates the number of cases. ED, 
extensive disease; LD, limited disease; PF, pleural 
fluid; W/B, washing/brushing; FNA, fine needle 
aspiration.
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lines harboring RET mutations (Table 1). We also looked for 
RET mutations in other reports of SCLC tumors6,7,11 and cell 
lines.12 Although we did not find any other occurrence of the 
RET M918T mutation, we did find four tumors and two cell 
lines with additional RET mutations, mainly within the tyro-
sine kinase domain (Table 1). Notably, several RET mutations 
were predicted to produce structural and/or functional effects 
using either the PolyPhen-2 or SIFT program.
RET Signaling and Inhibition in SCLC Cells
The mutant RET M918T receptor demonstrates high 
transforming activity relative to WT receptor in NIH3T3 
cells.13 We, therefore, prepared stable pools of two SCLC 
cell lines, H1048 and SW1271, which overexpressed either 
WT or M918T RET receptors (Fig. 3A and B) and looked 
for differential effects on cell signaling and proliferation. 
Western blotting experiments demonstrated that downstream 
MYC expression and ERK signaling were activated more by 
mutant versus WT RET receptors, both in the absence and 
in the presence of added GDNF ligand (Fig. 3B and C). The 
greater downstream signaling by mutant M918T versus WT 
RET receptor in SW1271 cells compared with H1048 cells 
most likely reflects the different relative expression levels of 
the exogenous RET receptors observed in these cells (Fig. 3A 
and B). ERK activation in the original tumor specimen was 
also observed (Fig. 2). Greater cell proliferation could also be 
demonstrated in mutant compared with WT cells, measured 
by either confluence (Fig. 4A) or MTT (Fig. 4B) assays. Cells 
expressing either RET receptor grew more rapidly than the 
parental (control) cells. These data are consistent with RET 
M918T acting as an oncogene in SCLC.
If RET overexpression was driving cell proliferation, 
then it should also sensitize these cells to tyrosine kinase 
inhibitors of RET. As shown in Figure 4C, ponatinib was a 
more potent inhibitor than vandetanib, and neither inhibitor 
produced similar growth inhibition in the parental cells, indi-
cating that the stable cells were indeed sensitized to tyrosine 
kinase inhibitors. Interestingly, there was little difference in 
growth inhibition of WT versus M918T mutant stable cells.
Variable RET Expression in Lung Cancer
Although M918T mutant cells were significantly more 
proliferative compared with transfected WT cells, WT RET 
and M918T RET cells were similarly inhibited by RET inhib-
itors. Thus, we wondered whether changes in RET global 
expression might contribute to the SCLC phenotype. Initially, 
we compared RET mRNA expression in various cancer cell 
FIGURE 2.  Immunohistochemistry (IHC) of RET and p-ERK 
in tumor no. 22. IHC for RET (left panels) and p-ERK (right 
panels) are shown for two different areas of the tumor. 
Images were captured at ×200. Ret positivity was observed 
in most of the tumor and demonstrated moderate to strong 
staining of cytoplasm and cell membranes. Phospho-Erk posi-
tivity was less consistent than Ret but demonstrated strong 
nuclear and light cytoplasmic staining when present. The 
high nuclear content and small cell size characteristic of SCLC 
are evident.
TABLE 1. RET mutations in Small-Cell Lung Cancer
Sample Change in cDNA Change in Protein Exon Domain Allelic Frequency PolyPhen-2 SIFT Ref
Tumor C1065A T278N 4 0.33 Benign Tolerated 6
Tumor C1991A A664D 11 N/A Possibly damaging Damaging 11
Tumor G2459T R820L 14 PTK N/A Probably damaging Damaging 7
Tumor T2753C M918T 16 PTK 0.63 Probably damaging Damaging P
Tumor G3383A A1051T 19 0.41 Benign Tolerated 6
H1339 G1282A E428K 7 0.43 Possibly damaging Tolerated 12
H865 G2140T D714Y 12 0.98 Probably damaging Damaging P
H1092 T2371A Y791N 13 PTK 0.52 Possibly damaging Damaging P/12
H1105 G2482C G828R 14 PTK 0.98 Probably damaging Tolerated P/12
H2066 T2558A S853T 14 PTK 0.51 Probably damaging Tolerated 12
H128 T2710A S904T 15 PTK 0.24 Probably damaging Damaging P
H1688 C2917A P973T 17 PTK 0.48 Probably damaging Damaging P
H1092 C3315T A1105V 20 0.47 Probably damaging Tolerated 12
N/A, not available; PTK, protein tyrosine kinase; Ref, reference; P, present study.
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lines using data from the Cancer Cell Line Encyclopedia12 and 
found that SCLC cells express relatively high levels of RET 
mRNA transcripts compared with most cancer cells, includ-
ing NSCLC cells (see Figure 3, Supplemental Digital Content 
2, http://links.lww.com/JTO/A675). We then focused on the 
expression of RET transcripts in specific thoracic cancers, 
shown in Figure 5A, compared with neuroblastoma, which 
demonstrated the highest RET expression levels among all 
cancer cells. It was clear that although RET expression was 
generally much lower in SCLC compared with neuroblastoma 
cells, a subgroup of SCLC cells expressed RET at the same 
high levels seen in neuroblastoma cells. The variability in 
SCLC RET expression was not due to changes in copy number 
(data not shown). Compared with NSCLC cells, RET mRNA 
expression in SCLC cells was significantly greater than that 
observed in adenocarcinoma cells (p < 0.05) but was not sig-
nificantly different from squamous- or large-cell carcinoma 
cells.
We initially validated the variable level of RET mRNA 
expression using gene array data from a recent study of 15 
SCLC tumors.7 The results, shown in Figure 5B, demonstrate 
that RET expression, normalized to β-actin, varies 272-fold 
among SCLC tumors. This contrasts with the expression of 
phosphatase and tensin homolog (PTEN), also located on chro-
mosome 10q and expressed at approximately equivalent levels 
to RET, which varies by only fourfold. Epidermal growth fac-
tor receptor (EGFR) expression differed by only 30-fold, fur-
ther highlighting RET expression variability in SCLC. We then 
examined RET expression among multiple thoracic cancers by 
immunohistochemical staining of a tissue microarray (TMA), 
as shown in Figure 5C. Small-cell lung carcinoma demon-
strated the highest percentage of strongly positive cores (80%), 
although only five such samples were present in the TMA, lim-
iting any broad interpretation of these results. Squamous- and 
adenocarcinomas, which were represented by a greater number 
of samples in the TMA (25 and 21, respectively), each dem-
onstrated a majority of strongly positive cores (60% and 50%, 
respectively). Large cell, carcinoid, and mesothelioma cores 
demonstrated low to medium positive staining but were repre-
sented by few samples. Examples of strong RET positivity are 
shown in Figure 5D. Taken together, our data indicate a wide 
variability in RET mRNA expression in both SCLC cells and 
tumors, although variable RET expression at a protein level in 
SCLC needs validation in a larger cohort. RET protein expres-
sion was variable, however, in NSCLC.
DISCUSSION
Our study is the first to identify an oncogenic somatic 
RET M918T mutation in SCLC. RET mutations underlie all 
forms of MTC, and the RET M918T mutation in particular is 
present in 95% of all MTC patients with hereditary MEN2B 
syndrome.8,9 The oncogenic potential of the RET M918T 
mutation in the setting of SCLC was shown by increased ERK 
activation, MYC expression, and cell proliferation in two cell 
lines with stable RET M918T receptor expression (Figs. 3 and 
4). Our discovery of a RET mutation in SCLC is not an isolated 
event, although our finding of an M918T mutation is unique. 
Remarkably, most RET mutations were located in the tyrosine 
kinase domain, potentially affecting receptor signaling func-
tion (Table 1). When the SCLC RET mutations were compared 
with those annotated in the MEN2 mutation database hosted 
by the University of Utah (http://www.arup.utah.edu/database. 
Accessed December 2013), which lists 159 RET variants, there 
were three amino acids mutated in both SCLC and MEN2: 
residues 791, 904, and 918. The Y791N SCLC mutation is an 
exact match to one found in the MEN2 database, whereas the 
S904T SCLC mutation is unique to SCLC. The RET A664D 
mutation, found by Futami et al.11 in two SCLC tumors, occurs 
A B
C
β
∆∆
FIGURE 3.  Stable RET expression and signaling 
in small-cell lung cancer cell lines. A, RET expres-
sion levels determined by qPCR in parental (Con) 
versus wild-type (WT) and M918T mutant (Mut) 
RET overexpressing H1048 and SW1271 cells. Levels 
were normalized to β-actin. B, Western blot of total 
RET (150–170 kDa) and MYC expression in parental 
(C) versus WT and M918T mutant (Mut) RET H1048 
and SW1271 cells. β-actin was used as a loading 
control. C, Western blot of ERK phosphorylation 
in parental (C) versus WT (W) and M918T mutant 
(M) RET H1048 and SW1271 cells under basal and 
GDNF (ng/ml) stimulated conditions (10 minutes) 
in serum-free medium. A longer exposure of the 
p-ERK blot (+) is shown to demonstrate increased 
ERK activation in H1048 cells under basal and 5 ng/
ml GDNF conditions.
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in the extracellular domain (exon 11). RET mutations in exons 
10 and 11, encoding the cysteine-rich domain of the recep-
tor, are also frequently observed in thyroid cancers associ-
ated with MEN2A syndrome. Although many of the observed 
SCLC RET mutations listed in Table 1 have yet to be validated, 
the majority of them are predicted to have functional effects. 
Furthermore, their occurrence in MEN2 syndromes, along 
with their abundance in the tyrosine kinase domain, suggests 
a potential role in some cases of SCLC. Given that RET muta-
tions are important in both thyroid medullary cancer and pheo-
chromocytoma, both neuroendocrine in nature like SCLC,2 it 
is possible that RET mutations play a significant role in sub-
groups of neuroendocrine cancers.
Several recent reports have identified KIF5B-RET 
fusions in NSCLC patients that are considered new driver 
mutations because they segregate from other typical muta-
tions such as EGFR, RAS, and ALK.14–17 RET fusions are 
rare events, estimated to occur in only 1% to 2% of patients, 
typically with adenocarcinoma.18 Their discovery was tre-
mendously aided, however, by the large cohorts of patients 
examined, which included 561, 936, and 1529 patients.15–17 By 
comparison, the two recent studies on comprehensive SCLC 
genomics included cohorts of only 406 and 677 patients and 
not all analyses (mutations, CNV, RNAseq) were completed 
on all samples. Thus, the role of oncogenic RET mutations 
in SCLC cannot be judged fairly until a larger number of 
tumors is studied, including metastatic tumors. It should be 
noted, however, that no other activating mutation was identi-
fied among the 19 oncogenes assayed in the tumor harboring 
the RET M918T mutation, potentially making RET M918T 
the responsible “driver” mutation in this tumor. Similarly, the 
majority of SCLC cell lines and tumors listed in Table 1 har-
bor only 0 to 1 mutations among these 19 oncogenes, although 
mutations of unknown significance in other consensus cancer 
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FIGURE 4.  Cell growth in stable RET SCLC cells. A, Growth curves in serum-free medium for parental (C) cells versus MUT and 
wild-type (WT) RET overexpressing H1048 and SW1271 cells. Growth was measured as percent confluence using the IncuCyte 
ZOOM. B, Cell growth in serum-free medium was measured by the MTT assay after 3 days. C, Dose-response of growth inhibi-
tion by vandetanib and ponatinib (in μM) using the MTT assay. Drugs were present for 1 (ponatinib) and 5 (vandetanib) days. 
All values are normalized to their respective control (no drug).
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genes were present (see Table 2, Supplemental Digital Content 
1, http://links.lww.com/JTO/A675). These data reflect the 
high mutational burden associated with lung cancer.
Our finding that RET exhibits widely variable expres-
sion in SCLC and can increase proliferation of SCLC cell 
lines stably overexpressing WT RET provides further evi-
dence that RET may play a role in the pathogenesis of this 
disease. Interestingly, RET expression in lung adenocarci-
noma was recently shown to be associated with shorter overall 
survival, but only in tumors coexpressing ASCL1, a neuroen-
docrine marker.19 Because ASCL1 is expressed in essentially 
all SCLC tumors, this suggests that high RET expression in 
SCLC may have a similar negative effect on survival. Our 
studies also demonstrate that cells stably overexpressing WT 
RET are sensitive to growth inhibition by RET-targeted tyro-
sine kinase inhibitors such as vandetanib, which is Food and 
Drug Administration–approved for treating thyroid medullary 
carcinoma,20,21 and ponatinib, which is currently in clinical tri-
als for NSCLC harboring RET fusion proteins. Thus, patients 
harboring lung carcinomas with elevated RET protein expres-
sion may benefit from treatment with RET kinase inhibitors. 
Although several randomized clinical trials of vandetinib in 
lung cancer were reported as negative, including SCLC,22–25 
it is possible that these results could be improved by patient 
enrichment for high RET expression. Indeed, one study sug-
gests that the development of a biomarker may improve van-
detanib efficacy in NSCLC.26
Our analysis is the first to quantitatively outline the 
types and frequency of diagnostic specimens obtained from 
SCLC patients during routine treatment of their disease. 
The data in Figure 1 clearly show that although the major-
ity of diagnostic specimens obtained from SCLC patients 
are biopsies (75%), only a very small minority of these 
biopsies (11% or 2.7%) are surgical resections. This is in 
stark contrast to the routine treatment of NSCLC, where 
more than 30% of patients undergo surgical resection. 
Moreover, all the resections in our SCLC cohort were from 
limited disease patients. Thus, our data support a view that 
the lack of progress in therapeutic innovation in SCLC can 
be traced back to a lack of sufficient tumor tissue required 
for thorough genomic and proteomic studies. Furthermore, 
genomic data of surgically resected SCLC primary tumors 
may not be representative of the disease, particularly when 
considering recent evidence that tumors evolve during 
metastasis.27 Thus, it is essential to capture more genomic 
data on metastatic SCLC tumors to obtain a full view of 
this disease.
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FIGURE 5.  RET expression in lung cancer. A, RET mRNA expression in lung cancer and neuroblastoma cell lines. The line within 
individual boxes represents the median mRNA expression value of all tested cells, and the circles represent “outlier” cells whose 
mRNA values do not fall within the 25% to 75% quartile of all mRNA values measured for that subtype (represented by the box). 
The numbers in parentheses indicate the number of cell lines assayed for RET expression for each subtype. B, Transcript levels of 
RET, PTEN, and EGFR in a cohort of 15 SCLC tumors reported by Peifer et al.7 Expression was individually normalized to β-actin 
levels for each tumor. C, Scoring table for RET immunohistochemistry (IHC) in thoracic cancer tissue microarray measured as high 
(3+), medium (2+), or low (1+) positivity. Count = number of cores analyzed. D, Examples of strong RET IHC staining in neuro-
blastoma (N), small-cell (SC), adeno- (Ad) and squamous-cell (Sq) lung carcinoma. Images were captured at ×200.
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